Domain Therapeutics Appoints New CMO as GPCR-Targeted Pipeline Advances

NEW YORK, NY – November 13, 2025

Leadership Change Signals Commitment to Clinical Progress

Domain Therapeutics, a biopharmaceutical company specializing in therapies targeting G protein-coupled receptors (GPCRs), has announced the appointment of Jean-Marie Cuillerot, M.D., as Chief Medical Officer (CMO). This strategic move comes as the company advances its lead candidate, DT-7012, a Treg-depleting anti-CCR8 antibody, through a Phase I/II clinical trial. The appointment underscores Domain’s commitment to accelerating its clinical programs and bringing innovative immuno-oncology and inflammatory disease therapies to market.

Cuillerot brings over two decades of experience in oncology drug development, clinical strategy, and regulatory affairs to Domain Therapeutics. He has held leadership positions at several prominent biotech and pharmaceutical companies, including Acrivon Therapeutics, Dragonfly Therapeutics, and Agenus. His prior roles at Merck Serono and Bristol-Myers Squibb involved the clinical development of pivotal cancer therapies, including avelumab and ipilimumab. “The depth of experience Dr. Cuillerot brings to Domain is invaluable,” noted one industry analyst. “His track record of successfully navigating drugs through the clinical pathway will be crucial as the company enters critical phases of development.”

Pioneering GPCR-Targeted Immunotherapies

Domain Therapeutics distinguishes itself through its focused approach on GPCRs, a vast family of membrane proteins that play a crucial role in cellular signaling and are implicated in a wide range of diseases. While traditionally under-explored as drug targets in oncology, GPCRs are gaining increasing recognition for their potential in modulating the tumor microenvironment and enhancing anti-tumor immunity. The company's pipeline leverages its proprietary platforms, such as DTect-All™ and bioSens-All™, to identify and characterize GPCR binders, enabling the development of highly selective and potent therapies.

DT-7012, the company’s lead candidate, is designed to deplete regulatory T cells (Tregs) in the tumor microenvironment. Tregs suppress the immune system, allowing cancer cells to evade detection and destruction. By selectively depleting Tregs, DT-7012 aims to unleash the anti-tumor immune response and improve the efficacy of existing cancer therapies. The Phase I/II DOMISOL trial, currently underway in Australia, is evaluating the safety and efficacy of DT-7012 in patients with advanced solid tumors. Preliminary data is expected to shed light on the antibody’s ability to modulate the tumor microenvironment and induce anti-tumor activity.

Beyond DT-7012, Domain’s pipeline includes DT-9081, an EP4 receptor antagonist, and DT-9046, a PAR2 modulator. DT-9081 is being evaluated in a Phase I trial for patients with advanced solid tumors, while DT-9046 is progressing through pre-IND studies. These programs demonstrate the breadth of Domain’s GPCR-focused platform and its commitment to addressing unmet medical needs in immuno-oncology and inflammation.

Funding and Partnerships Fuel Growth

Domain Therapeutics has secured significant funding to support its pipeline development. The company has raised over $51.2 million through multiple funding rounds, including a $42 million Series A round in May 2022. This funding has enabled Domain to accelerate its clinical programs and expand its research capabilities. A significant portion of the funding is allocated toward completing the Phase I/II trials of DT-7012 and progressing its other pipeline candidates.

In addition to financial backing, Domain has established strategic partnerships with several pharmaceutical and biotech companies. These collaborations provide access to valuable expertise, resources, and potential commercialization opportunities. Key partners include Pfizer, Merck, and Boehringer Ingelheim. These collaborations focus on a variety of areas, including target validation, drug discovery, and clinical development. Domain’s collaborative approach highlights its commitment to leveraging external expertise and accelerating the development of innovative therapies. Domain has also made strategic investments and acquisitions to further strengthen its pipeline and technology platform.

The increasing recognition of GPCRs as critical therapeutic targets, coupled with Domain’s proprietary technology and strong financial backing, positions the company for continued growth and success. While the immuno-oncology field is highly competitive, Domain’s unique focus on GPCRs and its commitment to developing innovative therapies differentiate it from other players in the market. Industry analysts anticipate that the company will continue to attract investment and forge strategic partnerships as it advances its pipeline and brings new therapies to patients. “Domain Therapeutics has built a compelling platform and a strong pipeline,” said one venture capital investor. “We are optimistic about its potential to deliver innovative therapies and generate significant value for patients and shareholders.”